{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:42:35Z","timestamp":1769557355384,"version":"3.49.0"},"reference-count":27,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK107680"],"award-info":[{"award-number":["DK107680"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>The results of the present study demonstrate that beta cell function in newly diagnosed T2DM patients is the key predictor of response to glucose lowering medications and provides a practical tool (C-Pep120 \/C-Pep0) to guide the choice of glucose lowering agent.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This work aims to identify predictors for individualization of antidiabetic therapy in patients with new-onset type 2 diabetes mellitus (T2DM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 261 drug-naive participants in the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) study, with new-onset diabetes, were randomly assigned in a single-center study to receive 1) metformin followed by glipizide and then insulin glargine on failure to achieve glycated hemoglobin A1c (HbA1c) less than 6.5%, or 2) initial triple therapy with metformin\/pioglitazone\/exenatide. Each patient received a 75-g oral glucose tolerance test (OGTT) prior to start of therapy. Factors that predicted response to therapy were identified using the area under the receiver operating characteristic curve method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-nine patients started and maintained the treatment goal (HbA1c\u2005&amp;lt;\u20056.5%) on metformin only, and did not require intensification of antihyperglycemic therapy; 54 patients required addition of glipizide to metformin; and 47 patients required insulin addition to metformin plus glipizide for glucose control. The plasma C-peptide concentration (C-Pep)120\/C-Pep0 ratio during the OGTT was the strongest predictor of response to therapy. Patients with a ratio less than 1.78 were more likely to require insulin for glucose control, whereas patients with a ratio greater than 2.65 were more likely to achieve glucose control with metformin monotherapy. In patients started on initial triple therapy, the HbA1c decreased independently of the C-Pep120\/C-Pep0 ratio.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The increase in C-Pep above fasting following glucose load predicts the response to antihyperglycemic therapy in patients with new-onset diabetes. C-Pep120\/C-Pep0 provides a useful tool for the individualization of antihyperglycemic therapy in patients with new-onset T2DM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab403","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T18:36:04Z","timestamp":1628015764000},"page":"3497-3504","source":"Crossref","is-referenced-by-count":6,"title":["Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes"],"prefix":"10.1210","volume":"106","author":[{"given":"S","family":"Abdelgani","sequence":"first","affiliation":[{"name":"Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Puckett","sequence":"additional","affiliation":[{"name":"Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Adams","sequence":"additional","affiliation":[{"name":"Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Triplitt","sequence":"additional","affiliation":[{"name":"Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3839-1724","authenticated-orcid":false,"given":"R A","family":"DeFronzo","sequence":"additional","affiliation":[{"name":"Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4556-1787","authenticated-orcid":false,"given":"M","family":"Abdul-Ghani","sequence":"additional","affiliation":[{"name":"Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2021,8,3]]},"reference":[{"issue":"6","key":"2022012510083646100_CIT0001","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41574-020-0334-z","article-title":"Young-onset type 2 diabetes mellitus\u2014implications for morbidity and mortality","volume":"16","author":"Magliano","year":"2020","journal-title":"Nat Rev Endocrinol."},{"issue":"4","key":"2022012510083646100_CIT0002","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes."},{"issue":"6","key":"2022012510083646100_CIT0003","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/diab.37.6.667","article-title":"Lilly Lecture 1987. The triumvirate: \u03b2-cell, muscle, liver. A collusion responsible for NIDDM","volume":"37","author":"DeFronzo","year":"1988","journal-title":"Diabetes."},{"issue":"12","key":"2022012510083646100_CIT0004","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1172\/JCI25151","article-title":"Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents","volume":"115","author":"Morino","year":"2005","journal-title":"J Clin Invest."},{"issue":"3","key":"2022012510083646100_CIT0005","doi-asserted-by":"crossref","first-page":"E537","DOI":"10.1152\/ajpendo.00541.2003","article-title":"Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes","volume":"287","author":"Kashyap","year":"2004","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"1","key":"2022012510083646100_CIT0006","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-002-1009-0","article-title":"The relative contributions of insulin resistance and \u03b2-cell dysfunction to the pathophysiology of type 2 diabetes","volume":"46","author":"Kahn","year":"2003","journal-title":"Diabetologia."},{"issue":"3","key":"2022012510083646100_CIT0007","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-8587(20)30022-X","article-title":"Inadequate \u03b2-cell mass is essential for the pathogenesis of type 2 diabetes","volume":"8","author":"Weir","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"2022012510083646100_CIT0008","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","article-title":"Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study","volume":"7","author":"Zaharia","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"2022012510083646100_CIT0009","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9131","key":"2022012510083646100_CIT0010","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group.","year":"1998","journal-title":"Lancet."},{"issue":"12","key":"2022012510083646100_CIT0011","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care."},{"issue":"11","key":"2022012510083646100_CIT0012","first-page":"4059","article-title":"Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus","volume":"81","author":"Cusi","year":"1996","journal-title":"J Clin Endo Metab."},{"issue":"23","key":"2022012510083646100_CIT0013","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med."},{"issue":"6972","key":"2022012510083646100_CIT0014","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bmj.310.6972.83","article-title":"United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years","volume":"310","year":"1995","journal-title":"BMJ."},{"issue":"3","key":"2022012510083646100_CIT0015","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/dom.12417","article-title":"Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial","volume":"17","author":"Abdul-Ghani","year":"2015","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"2022012510083646100_CIT0016","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2337\/dc20-0978","article-title":"Durability of triple combination therapy versus stepwise addition therapy in patients with new-onset T2DM: 3-year follow-up of EDICT","volume":"44","author":"Abdul-Ghani","year":"2021","journal-title":"Diabetes Care."},{"issue":"5","key":"2022012510083646100_CIT0017","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2337\/db05-1200","article-title":"Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study","volume":"55","author":"Abdul-Ghani","year":"2006","journal-title":"Diabetes."},{"issue":"9","key":"2022012510083646100_CIT0018","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care."},{"issue":"2","key":"2022012510083646100_CIT0019","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2337\/db11-0995","article-title":"Distinct \u03b2-cell defects in impaired fasting glucose and impaired glucose tolerance","volume":"61","author":"Kanat","year":"2012","journal-title":"Diabetes."},{"issue":"7","key":"2022012510083646100_CIT0020","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia."},{"issue":"3","key":"2022012510083646100_CIT0021","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/picr.PICR_87_18","article-title":"Understanding diagnostic tests\u2014part 3: receiver operating characteristic curves","volume":"9","author":"Aggarwal","year":"2018","journal-title":"Perspect Clin Res."},{"issue":"3","key":"2022012510083646100_CIT0022","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics."},{"issue":"1","key":"2022012510083646100_CIT0023","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer."},{"key":"2022012510083646100_CIT0024"},{"issue":"9","key":"2022012510083646100_CIT0025","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2337\/dc11-0291","article-title":"Effects of exenatide on measures of \u03b2-cell function after 3 years in metformin-treated patients with type 2 diabetes","volume":"34","author":"Bunck","year":"2011","journal-title":"Diabetes Care."},{"key":"2022012510083646100_CIT0026","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.2337\/dcS13-2003","article-title":"In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion","volume":"36","author":"Eldor","year":"2013","journal-title":"Diabetes Care."},{"issue":"4","key":"2022012510083646100_CIT0027","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dom.13189","article-title":"Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal\/bolus insulin in poorly controlled T2DM patients: results from the Qatar study","volume":"20","author":"Abdul-Ghani","year":"2018","journal-title":"Diabetes Obes Metab."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab403\/39698119\/dgab403.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/12\/3497\/42264021\/dgab403.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/12\/3497\/42264021\/dgab403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T10:09:09Z","timestamp":1643105349000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/12\/3497\/6338179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,3]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,8,3]]},"published-print":{"date-parts":[[2021,11,19]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab403","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,8,3]]}}}